Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicountry Prospective Safety Study of Ad26.ZEBOV and MVA-BN-Filo
2015-004139-11Phase 3
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3 trial of zabdeno and Mvabea in Ebola virus disease (EVD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Incidence of participants with Serious Adverse Events (SAE).
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on 2015-004139-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004139-11.